Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-1019 Combinations in Metastatic Solid Tumors
NCT06576037Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2024
- Primary completion
- Jun 2027
- Modality
- Cytotoxic ADCs, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of CBP-1019 in solid tumor (8 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
CBP-1019
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06576037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06576037.